Partner with CIHR on the European Union Joint Programme on Neurodegenerative Disease (JPND) Research
With 30 member countries, the EU Joint Programme – Neurodegenerative Disease Research (JPND) is the largest global research initiative aimed at tackling the challenge of neurodegenerative diseases. JPND increases and coordinates the research investments of participating countries. By working together, the goal is to accelerate research that supports early diagnosis and treatment, improves patient care, and, ultimately, leads to cures for neurodegenerative diseases.
JPND has identified common research goals to drive joint action in the search for solutions for patients, families, and health care providers.
There are three main components to this work:
- Improve the scientific understanding of the disease.
- Improve the medical tools available to doctors to identify and treat the disease.
- Improve the social care and structures available to assist patients, their families, and health service providers so that patients can receive optimum care at all stages of their illness.
Canada's involvement in numbers
Canada, represented by the CIHR Institutes of Aging and Neurosciences, Mental Health and Addiction, joined in 2012 as the first Third Country member.
Since then, Canada has:
- Participated in 5 calls and invested $3.8 million
- Funded the Canadian component of 10 multinational research teams
- Committed $700,000 to the 2018 JPND call on health and social care for neurodegenerative diseases and the Public Health Agency of Canada partnered with us
- Committed $500,000 to the 2019 JPND call on personalized medicine for neurodegenerative diseases
The 2020 call
In January 2020, JPND will launch a call on “Novel imaging and brain stimulation methods and technologies related to Neurodegenerative Diseases”. JPND is launching this joint transnational call with a view to promote research aiming at the development of novel and the advanced use of existing cutting-edge imaging and brain stimulation technologies related to neurodegenerative diseases.
The aim is to establish a number of ambitious, innovative, multi-disciplinary and multi-national collaborative research projects that will add value to further advancing the development and the use of imaging technologies and brain stimulation techniques to better understand, treat or diagnose neurodegenerative diseases. Approaches must be translational and patient-centered and basic research and cost-effectiveness studies are encouraged where appropriate. They must be hypotheses-driven and combine cutting-edge technological developments with a clear, substantial research question.
Proposals will need to focus on one or more of the following neurodegenerative diseases:
- Alzheimer’s disease and other dementias
- Parkinson’s disease and related disorders
- Prion diseases
- Motor neuron diseases
- Huntington’s disease
- Spinocerebellar ataxia
- Spinal muscular atrophy
In addition, proposals must focus on one or more technologies or techniques:
- Imaging technologies such as MRI, PET, super-resolution microscopy, and molecular imaging.
- Brain stimulation techniques such as deep brain stimulation, neuromodulation, transcranial magnetic stimulation, and transcranial direct current stimulation.
Why partner on JPND with CIHR?
Canadian organizations are invited to partner with CIHR and support the participation of more Canadian researchers in projects funded under the 2020 call.
- Be part of Canada’s presence in the largest global research initiative on neurodegenerative diseases
- Increase the global impact of your organization
- Leverage your organization’s research funds
- Connect with an international network of researchers and funding agencies
|November 8, 2019||Pre-announcement|
|January 6, 2020||Official launch|
|March 3, 2020||Deadline for pre-proposals|
|May 15, 2020||Invitations for full proposals|
|June 30, 2020||Deadline for full proposals|
|October 12, 2020||Notice of decisions|
To discuss this opportunity, please contact:
Joanne Goldberg, Assistant Director of the CIHR Institute of Aging, at email@example.com.
- Date modified: